OOIR: Observatory of International Research

Papers

(The H4-Index of Journal of Nuclear Medicine is 50. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)

Article	Citations
Practicing Medicine in Wartime Ukraine	222
One Bite from the Apple, One Bite from the Orange in the PRECISE-MDT Study	144
Radiolabeled Somatostatin Receptor Antagonist Versus Agonist for Peptide Receptor Radionuclide Therapy in Patients with Therapy-Resistant Meningioma: PROMENADE Phase 0 Study	134
[ ¹⁷⁷ Lu]Lu-DOTATATE for Recurrent Meningioma (LUMEN-1, EORTC-2334-BTG): Study Protocol for a Randomized Phase II Trial	121
State of the Art: Precision Surgery Guided by Intraoperative Molecular Imaging	101
Response to the FDA Dosage Optimization Draft Guidance for Radiopharmaceutical Therapies	101
Localized In Vivo Prodrug Activation Using Radionuclides	91
Quantitative Deauville Scoring to Uncover Prognostic Information from ¹⁸F-FDG PET–Based Response Assessment: Data from the EuroNet-PHL-C1 Trial	91
Synergy Between Radiopharmaceutical Therapy and Immune Response: Deciphering the Underpinning Mechanisms for Future Actions	88
Biochemical Recurrence–Free Survival After Radical Prostatectomy in Patients with High-Risk Prostate Cancer: A Nationwide Study of PSMA PET/CT Versus Conventional Imaging	87
Serial [ ¹⁸ F]AlF-NOTA-FAPI PET/CT and CT Angiography in Type B Aortic Dissection Before and After Thoracic Endovascular Aortic Repair	79
Positron Range Correction Helps Enhance the Image Quality of Cardiac⁸²Rb PET/CT	76
Prostate-Specific Membrane Antigen–Targeted Imaging and Its Correlation with HOXB13 Expression	71
Beyond Average: α-Particle Distribution and Dose Heterogeneity in Bone Metastatic Prostate Cancer	69
Impact of Single-Time-Point Estimates of¹⁷⁷Lu-PRRT Absorbed Doses on Patient Management: Validation of a Trained Multiple-Linear-Regression Model in 159 Patients and 477 Therapy Cycles	67
Redesigned Curricula, Stringent Licensing Criteria, and Integrated Independence Are Conditions for a Bright Future for Nuclear Medicine in the United States	67
Delta-like Ligand 3–Directed ²²⁵ Ac Radioimmunotherapy in Neuroendocrine Lung and Prostate Cancer Models	66
Composite Prediction Score to Interpret Bone Focal Uptake in Hormone-Sensitive Prostate Cancer Patients Imaged with [¹⁸F]PSMA-1007 PET/CT	65
Prognostic Value of Comprehensive Analysis of Metastatic Prostate Tumor Changes from First to Last [ ¹⁷⁷ Lu]Lu-PSMA Therapy Injections Through Serial	64
Ambient Light Resistant Shortwave Infrared Fluorescence Imaging for Preclinical Tumor Delineation via the pH Low-Insertion Peptide Conjugated to Indocyanine Green	63
Preclinical Evaluation of²²⁶Ac as a Theranostic Agent: Imaging, Dosimetry, and Therapy	63
CCK₂Receptor Ligand [⁶⁸Ga]Ga-DOTA-CCK-66 PET/CT Outperforms [⁶⁸Ga]Ga-DOTATOC PET/CT in a Patient with Small Cell Lung Cancer	63
Determining Hemodynamically Significant Coronary Artery Disease: Patient-Specific Cutoffs in Quantitative Myocardial Blood Flow Using [¹⁵O]H₂O PET Imaging	63
Nuclear Medicine AI in Action: The Bethesda Report (AI Summit 2024)	62
Diagnostic Performance of [ ¹⁸ F]PSMA-1007 PET/CT on Proven PSMA-Positive Hepatocellular Carcinoma: A Prospective Clinical Study	61

Interspecies Variability in Biodistribution and PET Imaging Performance of [¹⁸F]Di-PyL: A Dimeric, PSMA-Targeted PET Agent for Prostate Cancer	59
Quantitative Spatial Profiling of Antibody Delivery and Target Engagement Using Optically Labeled Antibodies	59
Receptor-Targeted Peptide Conjugates Based on Diphosphines Enable Preparation of^99mTc and¹⁸⁸Re Theranostic Agents for Prostate Cancer	58
MIRD Pamphlet No. 28, Part 2: Comparative Evaluation of MIRDcalc Dosimetry Software Across a Compendium of Diagnostic Radiopharmaceuticals	57
Clinical Experience with [²²⁵Ac]Ac-PSMA Treatment in Patients with [¹⁷⁷Lu]Lu-PSMA–Refractory Metastatic Castration-Resistant Prostate Cancer	56
¹⁷⁷Lu-DOTATATE in Combination with PARP Inhibitor Olaparib Is Feasible in Patients with Somatostatin-Positive Tumors: Results from the LuPARP Phase I Trial	56
Preclinical Evaluation of ⁶⁴ Cu-LNTH-1363S to Detect Cardiac FAP-Positive Fibroblasts Using PET Imaging	55
Preclinical Characterization of the Tau PET Tracer [¹⁸F]SNFT-1: Comparison of Tau PET Tracers	55
Impact of PET Reconstruction on Amyloid-β Quantitation in Cross-Sectional and Longitudinal Analyses	55
Precision Medicine Clinical Trials	55
Correlation of SUV on Early Interim PET with Recurrence-Free Survival and Overall Survival in Primary Operable HER2-Positive Breast Cancer (the TBCRC026 Trial)	55
⁶⁸Ga-PSMA PET/CT–Based Atlas for Prostate Bed Recurrence After Radical Prostatectomy: Clinical Implications for Salvage Radiation Therapy Contouring Guidelines	55
The Role of Molecular Imaging in Precision Oncology	54
Diagnostic Radiopharmaceuticals: A Sustainable Path to the Improvement of Patient Care	54
Translation of Intraoperative Molecular Imaging for Clinical Use	54
Reply to “Foregoing Nonclinical Dosimetry Studies to Support First-in-Human Studies of Certain PET Radiopharmaceuticals”	53
¹⁷⁷Lu-PSMA Radiopharmaceutical Therapy or Cabazitaxel?	53
Diuresis During¹⁸F-Flotufolastat (rhPSMA-7.3) PET/CT Improves Recurrence Detection After Prostatectomy: A Prospective Phase II Trial	52
Funding Reductions Threaten the Future of Medical Innovation	52
Malignancy Detection Rates of [ ⁶⁸ Ga]Ga-SSO120 PET/CT in Patients with Small Cell Lung Cancer and Large Cell Neuroendocrine Lung Cancer	51
2022 SNMMI Highlights Lecture: Oncology and Therapy, Part 2	51
Imaging Inflammation Past, Present, and Future: Focus on Cardioimmunology	51
α-Synuclein Seeding Amplification Assay: A Breakthrough in Diagnosing Parkinson Disease?	50
Development and Preclinical Evaluation of [⁶⁴Cu]Cu-NOTA-ABDB6: A CD70 and Albumin Dual-Binding Tracer with Improved Pharmacokinetics	50
Deep Learning–Based Attenuation Correction Improves Diagnostic Accuracy of Cardiac SPECT	50